iPSC– tag –
-
Reprogramming the Future: Liv Hospital Details iPSC Therapy’s Transformative Role in Regenerative Medicine
Liv Hospital Turkey Overview Liv Hospital recently published an insightful article on induced pluripotent stem cell (iPSC) therapy, highlighting its profound impact on regenerative medicine, diverse applications, and global clinical prog... -
Sana Biotechnology Advances Hypoimmune iPSC-Derived SC451 for Type 1 Diabetes and In Vivo CAR T SG293 for Non-Hodgkin Lymphoma Towards Clinical Entry, Bolstered by NEJM Publication of Long-Term Pancreatic Islet Data
Sana Biotechnology, Inc. (Press Release) USA Overview Sana Biotechnology reported significant progress towards initiating clinical trials for SC451, an iPSC-derived pancreatic islet cell therapy for Type 1 diabetes, and SG293, an in vivo... -
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of... -
Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing
Business Wire USA Overview Lineage Cell Therapeutics reported Q2 2026 financial results and business updates, confirming continued support for its OpRegen cell therapy development collaboration with Roche and Genentech, including technic... -
Fate Therapeutics Executives Sell Shares Post-FDA IND Approval for Next-Gen Autoimmune CAR-T Candidate FT839, Market Anticipates Basket Trial Success
TipRanks USA Overview Fate Therapeutics executives engaged in significant insider stock sales following news of the U.S. FDA's Investigational New Drug (IND) approval for FT839, its next-generation off-the-shelf CAR-T candidate for autoi... -
Aspen Neuroscience’s ANPD001 Cell Therapy for Parkinson’s Disease Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation, Signaling Accelerated Development
RegMedNet USA Overview A RegMedNet report indicates that Aspen Neuroscience's ANPD001 cell therapy for Parkinson's disease has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA, based on preliminary Pha... -
Liv Hospital Accelerates iPSC Therapy with Bioreactor Investment, Targeting Parkinson’s Disease
Liv Hospital Turkey Overview Liv Hospital is addressing the critical challenge of safe and efficient mass production of induced pluripotent stem cells (iPSCs) through a major investment in advanced bioreactor systems. This initiative aim... -
IPS HEART’s iPSC-Derived Cell Therapy ISX9-CPC Receives FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathy
StreetInsider USA Overview IPS HEART, Inc. announced that its iPSC-derived cell replacement therapy, ISX9-CPC, has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for cardiomyopathy associated with muscular dystrophi... -
RoosterBio and Applied StemCell Partner to Scale iPSC-Based Bioprocess Solutions, Accelerating Cell Therapy Manufacturing
MD Tech Council (Facebook) USA Overview RoosterBio and Applied StemCell have formed a strategic partnership to scale iPSC-based bioprocess solutions, aiming to accelerate the commercial production of cell therapies. This collaboration in... -
Vertex Pharmaceuticals Secures FDA IND Approval for iPSC-Derived Type 1 Diabetes Therapies, Boosts 2026 Revenue Forecast
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced robust Q2 2026 financial results and significantly raised its full-year revenue guidance, propelled by key pipeline advancements. The company secured FDA Investigationa...
